Items Tagged ‘Melanoma’

September 28th, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European Society for Medical Oncology and published simultaneously in the New England Journal of Medicine. There remains an unmet need for […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, nivolumab, opdivo, Precision Cancer Medicine, Yervoy


July 20th, 2017

Delaying Lymph Node Biopsy After Melanoma Diagnosis Does Not Affect Survival Rates

By

A lymph node biopsy occurring more than 30 days after diagnosis is unlikely to have an adverse effect on the patient’s overall prognosis Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn’t adversely impact long-term clinical outcomes according to new study findings published in the Journal of the American College of Surgeons […]

View full entry

Tags: B cell acute lymphoblastic leukemia, CAR technology, deaths, fda, Fludara, fludarabine, lymph node removal, Melanoma, News, ROCKET trial, surgery


July 18th, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

A clinical trial evaluating Opdivo  (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survival in patients receiving Opdivo compared to Yervoy. There remains an unmet need for additional treatment options for individuals with stage III and resected stage IV high-risk melanoma […]

View full entry

Tags: adjuvant therapy, checkmate-238, checkpoint inhibitor, Melanoma, News, nivolumab, opdivo, PD-1, Precision Cancer Medicine


June 15th, 2017

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) report that Keytruda is now associated with a 30% improvement in survival when used as initial treatment for advanced […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, PD-1, pembrolizumab, precison medicine, Yervoy


May 1st, 2017

Check It Out: May is Skin Cancer Awareness Month

By

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which accounts for approximately 1% of cases. In 2016, the ACS estimates 76,380 […]

View full entry

Tags: awareness, General Skin Cancer, infographic, Melanoma, News, Recurrent Melanoma, Screening/Prevention Melanoma, Skin Cancer, Stage III Melanoma, Stage IV Melanoma, Stages I-II Melanoma, support


April 19th, 2017

Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

By

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy (ipilumamab) and Opdivo (nivolumab) combinations has just been reported.  The two-year survival rates were 64% for the Opdivo plus Yervoy combination, 59% for Opdivo alone and 45% for Yervoy alone. About Opdivo Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is […]

View full entry

Tags: immunotherapy, Melanoma, News, opdivo, PD1


March 15th, 2017

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar (dabrafenib) + Mekinist (trametinib) combination therapy are alive versus 31% of patients on BRAF monotherapy with […]

View full entry

Tags: BRAF, mek, Mekinist (trametinib), Melanoma, News, Tafinlar (dabrafenib), Zelboraf (vemurafenib


October 24th, 2016

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

By

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with five-year OS rates at 65.4% […]

View full entry

Tags: 2016, advanced melanoma, ESMO, high-risk, ipilimumab, Melanoma, News, overall survival, stage III, Stage III Melanoma, Yervoy


October 11th, 2016

Epacadostat Plus Keytruda® Appears Effective in Melanoma

By

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery, melanoma has a high cure rate. However, once melanoma invades deeper tissues or spreads from its […]

View full entry

Tags: advanced, Epacadostat, keytruda, Melanoma, mole, News, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


September 20th, 2016

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

By

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination being considered as a new standard of care for patients with this disease. These results were recently published in the Lancet Oncology. Melanoma is a […]

View full entry

Tags: advanced, BRAF V600, cobimetinib, combination, Melanoma, metastatic, News, Stage III Melanoma, Stage IV Melanoma, vemurafenib


July 21st, 2016

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

By

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Advanced melanoma refers to skin […]

View full entry

Tags: 2016, advanced, asco, BRAFV600E/K mutation, COMBI-d trial, dabrafenib, kinase inhibitors, mekinist, Melanoma, News, Stage IV Melanoma, Taflinar


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen


December 2nd, 2015

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

By

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The indication for this expanded approval specifies that Opdivo can be used for treatment […]

View full entry

Tags: advanced, CheckMate -066 trial, Melanoma, metastatic, News, opdivo, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


November 9th, 2015

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma

By

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin cancer to spread from its site of origin to other sites in the […]

View full entry

Tags: Melanoma, News, Recurrent Melanoma, Stage III Melanoma


October 28th, 2015

Imlygic® Approved for Melanoma

By

Imlygic® (talimogene laherparepvec), the first ever FDA-approved oncolytic virus therapy, has been approved for the treatment of melanoma. The approval is for the treatment of melanoma sites in the skin and lymph nodes that cannot be surgically removed. Imlygic is given as an injection directly into the site of cancer, and is given through a […]

View full entry

Tags: Imylgic, Melanoma, News, oncolytic virus therapy, talimogene laherparepvec